Journal of travel medicine · 2025
Chikungunya vaccination for travellers: practical guidance for clinical decision-making.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hills Susan L, Shlim David R, Schofield Steven, Wilson Mary E, Barnett Elizabeth D, Chen Lin H, Christensen Kristin J, Staples J Erin
Аннотация
BACKGROUND: Two vaccines have been licensed to prevent chikungunya, a live attenuated vaccine (IXCHIQ) manufactured by Valneva and a virus-like particle chikungunya vaccine (VIMKUNYA) manufactured by Bavarian Nordic. One or both vaccines are now available in many countries globally, including Brazil, Canada, United Kingdom, United States and some European countries and territories.
KEY FINDINGS: While the absence of a head-to-head study limits comparative inferences, the two vaccines have several different characteristics that should be considered when advising individual travellers. We outline key information on the vaccines including immunogenicity and safety data, recommendations for use in travellers and guidance for use in pregnancy and breastfeeding.
CONCLUSION: Knowledge of the profiles and key features of the live attenuated and virus-like particle vaccines will enable healthcare providers to better advise travellers who are considering chikungunya vaccination.
KEY FINDINGS: While the absence of a head-to-head study limits comparative inferences, the two vaccines have several different characteristics that should be considered when advising individual travellers. We outline key information on the vaccines including immunogenicity and safety data, recommendations for use in travellers and guidance for use in pregnancy and breastfeeding.
CONCLUSION: Knowledge of the profiles and key features of the live attenuated and virus-like particle vaccines will enable healthcare providers to better advise travellers who are considering chikungunya vaccination.